07 · Financing & capital markets
Financing & capital markets
Bookmarks need a Mind Club sign-in. How sign-in works
No therapeutics financing of $5M or more found and counted from the window. SELLAS’s $150M offering, counted on 11.19, is expected to close on 11.20.
| Company | Item | Why it is not counted today |
|---|---|---|
| SELLAS Life Sciences | $150.0M public offering, priced 11.18 | Already counted in the 11.19 edition |
| MegaRobo | About $200M round, as reported | Lab automation, out of scope |
| Marker Therapeutics | $16.2M CPRIT award | A grant; grants are excluded |
| VitriVax | $87M Series C, dated 11.18 | Already counted in the 11.19 edition |
| Boltz | $110M Series A, as reported | AI models sold as tools, out of scope |
SELLAS pricing release (11.18) (opens another website in a new tab) Co; Renaissance Capital IPO news, read 11.20: no biotech IPO filed, set terms or priced in the window Press.
RED TEAM
GlobeNewswire’s search and the Business Wire newsroom did not load for our sweep, so a quiet day here may be a gap in coverage, not in the market. Analysis